{"url_path":"/sec/vyne/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","accession_number":"0001104659-26-065214","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":79,"has_tables":true,"body_markdown":"**** \n\n****\n\n \n\n \n\n \n\n**Item 9.01**\n**Financial Statements and Exhibits.**\n\n** **\n\n(d) Exhibits.\n\n \n\n**Exhibit** **Number**\n \n**Description**\n\n \n \n \n\n[99.1](tm2615387d1_ex99-1.htm)\n \n[Presentation, dated May 21, 2026.](tm2615387d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n****\n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nVYNE THERAPEUTICS INC.\n\n \n \n\nDate: May 21, 2026\nBy:\n/s/ Mutya Harsch\n\n \n \nMutya Harsch\n\n \n \nChief Legal Officer and General Counsel"}